ArticleMedComm2026
Human Coronavirus 229E Uses ORF4/4a to Antagonize the Host Restriction Factor SERINC5.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serine incorporator 5 (SERINC5) restricts the infectivity of various enveloped viruses, including HIV-1 and severe acute respiratory syndrome coronavirus 2. However, these pandemic viral pathogens have evolved mechanisms to counteract this restriction. Here, we examined the impact of all five human SERINC family members on the seasonal human coronaviruses (hCoVs) 229E and OC43, which account for up to 15% of global mild respiratory infections and can cause severe disease in vulnerable individuals. Our data show that both exogenous and endogenous SERINC1, SERINC3, and SERINC5 significantly reduce OC43 infectivity in human lung and liver cells but have little, if any, effect on 229E. Functional analyses revealed that both the 130-amino-acid ORF4a protein encoded by most laboratory 229E strains and the full-length 219 amino acid ORF4 protein encoded by clinical 229E isolates antagonize SERINC5 by promoting its relocalization to lysosomes and subsequent degradation. Finally, we show that endogenous SERINC5 expression in primary human lung cells inhibits infection by ORF4-deficient but not wild-type hCoV-229E. In conclusion, several SERINC proteins restrict hCoV-OC43, whereas hCoV-229E efficiently counteracts SERINC-mediated restriction by its ORF4/4a accessory proteins to ensure efficient production of fully infectious viral particles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.